(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other most ...

In other recent news, GSK plc announced that the US Food and Drug Administration has accepted the Biologics License Application for depemokimab, targeting asthma and chronic rhinosinusitis with nasal ...

Medicine Development Leader HBV Program at GSK. “Given this, there is an urgent need for innovative options that can offer lasting solutions for patients without the burden of continuous ...

NEW YORK CITY, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ...

Shortly after President Donald Trump won his second presidential election in the U.S. last fall, British drugmaker GSK came to federal prosecutors in New York, bearing intel from employees ...

Mepolizumab is additionally indicated for treating CRSwNP. Depemokimab, a novel treatment, differs from mepolizumab due to specific modifications in its amino acid sequence. These alterations enhance ...